on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TAGG Buyout by Microsoft?
Microsoft (MSFT) Will Buyout TagLikeMe (TAGG)_Just You Watch And See Predicts Sierra World Equity Review
HEADLINE: Microsoft (MSFT) Will Buyout TagLikeMe (TAGG)_Just You Watch And See Predicts Sierra World Equity Review. Oh yes, it's coming, do not say I did not call it says Sierra!! Remember Sierra told you FIRST! Sierra is blogging from New Orleans where she is staying in the French Quarter. Sierra will be partying on Bourbon Street this weekend! Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 5 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
Posted by Sierra World Equity Review at 5:38 PM Email ThisBlogThis!Share to TwitterShare to Facebook
Medical Marijuana (MJNA) Joint Venture or Acquisition By Big Pharmaceutical_Watch For Heavy Volume Green Days Predicts Sierra World Equity Review $TAGG to be Bought By Microsoft
HEADLINE: Medical Marijuana $MJNA Joint Venture or Acquisition By Big Pharmaceutical_Watch For Heavy Volume Green Days Predicts Sierra World Equity Review. Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 5 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
Great Basin Gold (GBG)_Movement Now That Gold Fields (GFI) Up & Running_Nkomo Pushing GBG Negotiations Ventures Sierra World Equity Review $TAGG to be bought out By Microsoft
HEADLINE: Great Basin Gold (GBG)_Movement Now Tha Gold Fields (GFI) Up & Running_Nkomo Pushing GBG Negotiations Ventures Sierra World Equity Review. The saga continues, end in sight predicts Sierra. Remember when this happens Sierra told you FIRST! Sierra is blogging from Key West this week after being on the road for the last couple of weeks. Catching up on some errands and partying at Sloppy Joes on Duval makes Sierra a happy camper. Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Famous for her HEADLINERS, Sierra made more correct calls in the last 4 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
what are you replying to?
$amBs thought to be bought $TAGG to be bought by Microsoft according Sierra
Amarantus BioSciences (AMBS) To Surge_Watch For Official PR_Acquisition By Pfizer (PFE) Predicts Sierra World Equity Review
HEADLINE: Amarantus BioSciences (AMBS) To Surge_Watch For Official PR_Acquisition By Pfizer (PFE) Predicts Sierra World Equity Review. Remember when this happens Sierra told you FIRST! Sierra is blogging from Key West this week after being on the road for the last couple of weeks. Catching up on some errands and partying at Sloppy Joes on Duval makes Sierra a happy camper. Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Famous for her HEADLINERS, Sierra made more correct calls in the last 4 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
$TAGG forecast to be bought by Microsoft and $SRGE is also looking good
Southridge Enterprises (SRGE) Profit Taking & Manipulation To Hold PPS Down For Accumulation Will End_Watch For Official PR On Potential Acquisition Coming Ventures Sierra World Equity Review
HEADLINE: Southridge Enterprises (SRGE) Profit Taking & Manipulation To Hold PPS Down For Accumulation Will End_Watch For Official PR On Potential Acquisition Coming Ventures Sierra World Equity Review. Down in early trading 15% this stock IS going to go back up fast says Sierra. Remember Sierra told you FIRST! Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Famous for her HEADLINERS, Sierra made more correct calls in the last 4 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
yeah but this is something they would use....I love it
and notice there are no sponsored ads results yet..like on google
and others......this is where the $ will come from- I think they may be in talks already with all the hype aps did on it-----the word about taglikeme is spreading fast.....and with just the stats of it gaining website traffic tells me that people are using it too because they have to go there first to put it on their web browser
I am EXCITED !
$TAGG
So it is apparent to me that Microsoft buys potential intellectual
property and then they make money from their acquisition.
This TAGG APP and search may give them an edge over their competitors IMO and I feel they may feel the same......the the big question is
FOR HOW MUCH?......how much more revenue can they generate in the future if 1,000,000's are going to taglikeme.com or app rather than the others to search.....
I think someone must know.....I think it could have 9 0's in potential advertising revenue!
$TAGG
Since Microsoft's first acquisition in 1987, it has purchased an average of six companies a year. The company purchased more than ten companies a year between 2005 and 2008, and it acquired 18 firms in 2006, the most in a single year, including Onfolio, Lionhead Studios, Massive Incorporated, ProClarity, Winternals Software, and Colloquis. Microsoft has made five acquisitions worth over one billion dollars: Skype (2011), aQuantive (2007), Fast Search & Transfer (2008), Navision (2002), and Visio Corporation (2000).
Is this Idea that Taglikeme has something that Microsoft could capitalize on? I say a BIG YES
$TAGG
Accumulation Over_TagLikeMe (TAGG)_To Rise Prior To Official PR of Microsoft (MSFT) Buyout Predicts Sierra World Equity Review
HEADLINE: Accumulation Over_TagLikeMe (TAGG)_To Rise Prior To Official PR of Microsoft (MSFT) Buyout Predicts Sierra World Equity Review. With the official announcement from TAGG that month to month unique viewers for September vs October increased 1800% look for TAGG to start going green with heavy volume says Sierra. Remember when this happens Sierra told you FIRST! Sierra is blogging from Key West this week after being on the road for the last couple of weeks. Catching up on some errands and partying at Sloppy Joes on Duval makes Sierra a happy camper. Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Famous for her HEADLINERS, Sierra made more correct calls in the last 4 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
THESE ALL CAME TRUE!!__ACCURATE SIERRA'S PREDICTIONS WITH LINKS _ARE YOU A BELIEVER YET!
$TAGG
$SRGE
$MJNA
$AMBS
no panic selling here....I may have exited a lil too early but am very happy with the $40,000 dollars profit I cashed out with..I was thrilled..It takes money to make money .......I said enough....Let's put it this way......I don't go leave my house unless I make at least $500 ......I usually make about a Grand a day Landscaping....so I have more than enough to risk to play with on these pennies.
GLTU
I live on LI (N.Y.C.)where the average home is $400,000 and the property taxes are $15 grand a year...
I was just giving my opinion and leave it as that
GLTU
Sierra was CORRECT-ANOTHER Accurate Call as Questcor Pharmaceuticals (QCOR) Rebounds
Vringo (VRNG) to become a SUPERSTAR - Google(GOOG) WILL Resolve Patent Trial, VRNG Shareholders to
Fresh start for Great Basin Gold (GBG)_Sierra World Equity Review was Correct_Partnership and DIP
Pacific Ethanol (PEIX) Sierra World Equity Review initiates Coverage - Sierra rates it a "BUY"
Sep 17, 2012
Yet Another Accurate Call from Sierra - Qsymia from Vivus (VVUS) Now Available in US Sooner Than
Nice find......Just looked at her track record and she must be the real deal......
Take a look for yourself
http://pressroom.prlog.org/SierraWorldEquityR/
Still on the sidelines waiting for the smoke to clear from the fire I started @ .005 I am on the hunt for the next big runner that is way undervalued. I like to 1000% + gain potential company's with limited risk downside. Was very happy with the 1.6 mil. cashed out from .005 @ .035 but I do not see this going up 1000% near term from here so mostly big dayraders here looking to pump up and make 10 to 20% a day but IMO I feel it will go down this week especially now knowing that they are still looking for more $.....it takes a lot of $ to get this off the ground .....100's of millions. I am now uncomfortable at this price JMO Just one Pr. stating that they are increasing A/S to a billion and this will go down faster than it came up....this makes me uncomfortable
I still believe their will be plenty of $$ to be made up here but the hype will cool down as the pps will before any significant gains 1000% +
Most likely after it comes back down to high .01's
This of course after most realize this is a long term play
GLTA $AMBS
$TAGG
$SRGE
$YLLC
$VRNG
$ANTH
$ONCS
$IMSC
Has anyone called TA to find out the current O/S....DEN?
This is the reason for all the bashers now......$TAGG
they are part of other smaller pumping groups that would NEED this to go down more for them to make more money and what other thing to grasp at than saying " APS is out so this is dead "
I assume APS has a long reputation of followers and (the others)they will do everything they can to bring doubt in your minds about Taglikeme. I go with my DD and the most important DD here is the popularity of its website gaining traffic increasingly fast.....
there are only about 200,000 websites
that are in between aps and tag in the world of about 6,500,000 (6.5 MILLION). and I'm sure APS has spent more $ and been around much longer than tag can someone tell us how long this pumping service has been around?
[i]Hold on to your shares ......this is going to be a fun ride
As you can see w/ the link their are still considerable amount of shorts on-board and are nervous as hell that their BIG BROTHER (aps)got out and they still need to.
SHORT REPORT
If you look at the chart you can see where all the pumpers jumped in with the volume increase ....it was around the price we are now at- before they got involved you can also see the uptrend in price- we are now much further than we were before with confirmation from
Website traffic website
If I'm not mistaken....looks like the #'s are better than yesterday......another 1000 websites passed(in US) and this will continue IMO- check the website everyday and you will see for yourself.
Why is is gaining in popularity......Because its Something everyone is excited about and they tell their friends about it.
It won't be long for this to be in the top 1000 in US and that is very Significant
finance.yahoo.com/q/bc?s=TAGG&t=3m&l=on&z=l&q=l&c=
Chart for Tagg
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous countries by year’s end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015. The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as it currently has more desirable features than that of Benlysta. Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to specific patient populations and has not been studied in combination with other biologics. These attributes of blisibimod including a different mechanism of action, will set it apart from Benlysta, Global Data concludes.
A Potential 36-Bagger Biotech
Anthera Pharmaceuticals (Nasdaq: ANTH ) could be a 36-bagger from here. Maybe more.
The company currently has a market cap around $100 million; Human Genome Sciences, which owned half of its lupus drug Benlysta, was taken out by GlaxoSmithKline (NYSE: GSK ) for $3.6 billion. Anthera still owns the full rights to its lupus drug, blisibimod, although Human Genome's pipeline was arguably better than Antera's. Half a drug probably outweighs a weak pipeline, but let's call it a potential $3.6 billion valuation.
Of course, it could also be worthless. We are talking about a potential new treatment for lupus, after all.
It's notoriously hard to prove that a drug is effective in treating lupus. Before Benlysta was approved, there was a 52-year drought in the approval of drugs specifically developed for treating the disease. Not that companies didn't try; drugs from Biogen Idec (Nasdaq: BIIB ) , Teva Pharmaceutical (Nasdaq: TEVA ) , BioMarin Pharmaceutical (Nasdaq: BMRN ) , and many others all failed to show that they were effective in lupus patients. The waxing and waning nature of the disease makes it hard to measure whether a drug is working.
Anthera ran into that problem with its phase 2 trial for blisibimod. The drug only showed a substantial effect in the most severe patients using the most stringent measurements for improvement of patients' symptoms.
So that's what Anthera is going with. Its two phase 3 trials will enroll patients with severe lupus that haven't improved using corticosteroids. The primary endpoint will be the percent of patients that improved at least eight points or more on the Systemic Lupus Erythematosus Response Index, or SRI, which measures patients' symptoms.
I think there's a good chance that blisibimod works, but proving it won't be a walk in the park. In the phase 2 trial, 26% of the pooled placebo patients reported an eight-point increase in their SRI score. That's an awfully large -- and likely awfully variable -- placebo effect that blisibimod needs to overcome.
Despite the potential, investors are right to discount the stock substantially given the potential risk. Invest if you like the thrill of potential monster returns, just keep it to a small percentage of your portfolio.
Hope I can Pick up more shares in the .08's before a pr. comes out on this Ranking
This is unbelievable.....we are almost up to taffic rank with Travelers insurance Company
The Travelers Companies (NYSE: TRV) is a large American insurance company. It is the second largest writer of U.S. commercial property casualty insurance and the third largest writer of U.S. personal insurance through independent agents. Travelers has headquarters in New York City with significant operations in St. Paul, Minnesota and Hartford, Connecticut.[1] It has been a component of the Dow Jones Industrial Average since June 8, 2009.[4]
They are 30,000 in US
http://www.alexa.com/search?q=www.mytravelers.com&r=site_screener&p=bigtop
The company has field offices in every U.S. state, plus operations in the United Kingdom, Ireland, Singapore, China, Canada, and Brazil. In 2011, the company reported revenues of US $25.5 billion and total assets of US $104.6 billion.
Travelers, through its subsidiaries and approximately 14,000 independent agents and brokers, provides commercial and personal property and casualty insurance products and services to businesses, government units, associations, and individuals. The company offers insurance through three segments:
positive #'s again on website traffic past up another 1000 websites in the psat 24 hrs. in Us....here are the #'s
Global Rank 268,542
United States 35,880 This is rather a low number considering there are over 650,000,000 websites
http://articles.businessinsider.com/2012-03-08/tech/31135231_1_websites-domain-internet
http://www.alexa.com/siteinfo/taglikeme.com#
this is going well just by word of mouth...I bet the teenagers are spreading it the fastest
Getting more excited by everyday
We have a winner here....the stats don't lie....and this is gaining popularity fast....
$TAGG $SRGE $AMBS $AAPL $GOOG $VRNG $YLLC
THE presentation is on Tuesday 11/13
Think about it, in a world where search engines and social media are completely taking over, isn’t the next logical billion-dollar idea to combine the two? That is precisely what TAGG has done.
report from Oct. 5th below.... It looks like their campaign is working on driving traffic to the site....check Stickie above
traffic translates into $$$ ...look at what some have done with getting traffic on Youtube....many have become Famous
We will look at the website analytics and its popularity increasing and that will make us all feel better about where this is headed...up
this is the start of report.....
Just yesterday, the company announced that it has launched a new user trial campaign in order to drive over five million new unique views to its website over a 120-day period.( hopefully we get a pr update soon....or was it just the other day they said an 1800% Increase)
The way we see it there are really only two ways this company can go.
1) It will continue to grow as it becomes the next big viral website (like Pinterest) and can soon leave its current trading price far behind.
Or
2) As it keeps attracting millions of people, it could catch the attention of one of the current Forbes 500 companies, which will buy it out. And what can that do to your investment?
So the question seems to no longer be “will TAGG make money?” but rather, “through which of these two means can TAGG make money?”
TAGG is still trading for very low prices compared to valuations that other start ups have been commanding recently when being bought out . Just think of Instagram which received a billion dollars from Facebook just a few months ago. There’s probably many of you that haven’t even heard of it yet they still got a billion bucks.
We highly recommend you buy TAGG if you have been looking for an amazing tech company to invest in but haven’t been able to get in for cheap. We consider TAGG to be extremely cheap at 10-20 cents!
If TAGG hits $1 we are looking at almost 900% additional gains from where it is sitting now
Anthera’s Lupus Drug Gets A Second Chance After Clinical Trial Disaster
by Bio-Wire • November 9, 2012 • Company Drama, FDA Catalysts, Value
http://www.bio-wire.com/archives/287
back in January when they had a 100 mil. offering it dipped then came back strong so i am hoping for the same....phase 3 is expensive....im just happy they have 45 mil. in cash and equivelants
yes...open for business
I am hoping for some news next week.....after convention
yeah thats a bit too soon ...maybe----its only 7 weeks away
Its more popular than Americanbulls already
http://www.alexa.com/search?q=www.americanbulls.com&r=site_screener&p=bigtop
And everyone knows what site traffic means.....advertisers for $$$ or Buyout......I am going to keep an Eye on this Site awareness increase
http://www.alexa.com/search?q=www.americanbulls.com&r=site_screener&p=bigtop
Here is some positive hard facts......I checked out the Site analytics at alexa and it was ranked at 47,000 yesterday and today it is at 37,000 in US. I believe it was over a mil. globally now down to...check it out for yourself.....the stats on the website and the dramatic increase in popularity....The last PR was significant
We passed up 10,000 sites in a day- still need far to go but I think this will spread like wildfire once they start a lil marketing
http://www.alexa.com/search?q=www.taglikeme.com&r=site_screener&p=bigtop
up from here .... bought more
<<ANTH .74 now goin up...Phase III drug>>
Major potential here
was $8 beg. of year
Check the chart
.75 now
$ANTH....<<<<look at the CHART>>>
.74 now
yes it does
Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 An...
HAYWARD, Calif., Nov. 1, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that an abstract of the results from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus erythematosus patients has been accepted as a late-breaking poster presentation at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP).
"We are pleased to have this opportunity to share the PEARLS-SC responder analyses and sub-population results with the rheumatology community," said Colin Hislop, MD, Anthera's Senior Vice President and Chief Medical Officer. "In PEARL-SC, blisibimod demonstrated a clinically meaningful treatment effect in patients with severe disease who continued to have active lupus despite corticosteroid use. This highlights blisibimod's potential to help patients with more active and severe disease as we move forward with our Phase 3 clinical trials."
The poster entitled, "Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus," is scheduled to be presented by Dr. Richard Furie on Tuesday, November 13, from 9 am – 11 am Eastern Time (Presentation Number L6).
The abstract is available online through the ACR website at www.rheumatology.org. In accordance with the conference's embargo policy, the poster will be uploaded to the Anthera website only after completion of the session.
About Blisibimod and PEARL-SC
BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care. A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.
Copyright 2012 PR Newswire
$ANTH Nasdaq .72 Phase III drug
61% Inst. Owned they bought 10% more recently
Looking for News Next week
could reach $2 short term
ANTH 61% INST. OWNED.Phase III drug .72
Looking for solid gains from here
Big Boys bought up 10% in last few days
positive results
News can push this over $2
$ANTH Phase III Drug at bottom now
10% increase in institution own last week
Nasdaq @ .71 lookin good
61% institution owned